Nifty
:
25709.85
Sensex
:
83952.19
124.55 (0.49%)
484.53 (0.58%)
Nifty
Sensex
:
:
25709.85
83952.19
124.55 (0.49%)
484.53 (0.58%)

Aurobindo Pharma Ltd.

Pharmaceuticals & Drugs - Global

Rating :
58/99

BSE: 524804 | NSE: AUROPHARMA

NSE BSE
1101.00
17-Oct-2025
  • Open
  • High
  • Low
  • Previous Close
  •  1106
  •  1113.5
  •  1092.8
  •  1106.30
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  938051
  •  1033679815.1
  •  1499.5
  •  1010

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 63,972.39
  • 18.86
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 63,678.58
  • N/A
  • 1.91

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 51.82%
  • 0.46%
  • 5.25%
  • FII
  • DII
  • Others
  • 14.21%
  • 25.17%
  • 3.09%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.68
  • 5.07
  • 8.47

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.52
  • 4.30
  • 12.10

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.59
  • -8.35
  • 21.84

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.23
  • 17.63
  • 20.37

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.32
  • 1.99
  • 1.96

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 9.69
  • 9.33
  • 10.01

Earnings Forecasts:

(Updated: 11-10-2025)
Description
2024
2025
2026
2027
Adj EPS
60.02
64.34
75.65
81.21
P/E Ratio
18.34
17.11
14.55
13.56
Revenue
31378.1
33311.7
36838.2
39744.8
EBITDA
6582.79
6843.06
7675.85
8145.76
Net Income
3485.88
3757.59
4445.63
4817.48
ROA
7.35
7.86
8.16
7.93
P/B Ratio
1.96
1.79
1.61
1.46
ROE
11.16
10.84
11.56
11.19
FCFF
1883.81
3467.24
3009.79
8534.46
FCFF Yield
2.99
5.5
4.78
13.55
Net Debt
-75.93
-980.87
-2048.74
-7907.32
BVPS
562.21
616.38
682.96
751.87

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Net Sales
7,868.14
7,567.02
3.98%
8,382.12
7,580.15
10.58%
7,978.52
7,351.78
8.53%
7,796.07
7,219.42
7.99%
Expenses
6,265.11
5,947.45
5.34%
6,590.20
5,907.34
11.56%
6,400.54
5,750.47
11.30%
6,229.93
5,845.98
6.57%
EBITDA
1,603.03
1,619.57
-1.02%
1,791.92
1,672.81
7.12%
1,577.98
1,601.31
-1.46%
1,566.14
1,373.44
14.03%
EBIDTM
20.37%
21.40%
21.38%
22.07%
19.78%
21.78%
20.09%
19.02%
Other Income
105.30
220.93
-52.34%
134.81
135.62
-0.60%
157.29
162.52
-3.22%
136.00
186.98
-27.26%
Interest
97.75
111.04
-11.97%
115.02
89.43
28.61%
118.48
75.55
56.82%
112.70
68.18
65.30%
Depreciation
405.70
404.18
0.38%
444.43
354.33
25.43%
418.53
423.27
-1.12%
382.28
417.50
-8.44%
PBT
1,204.88
1,325.28
-9.08%
1,367.28
1,242.56
10.04%
1,198.26
1,265.01
-5.28%
1,207.16
1,074.74
12.32%
Tax
382.60
405.67
-5.69%
432.26
322.55
34.01%
354.28
322.45
9.87%
390.51
323.70
20.64%
PAT
822.28
919.61
-10.58%
935.02
920.01
1.63%
843.98
942.56
-10.46%
816.65
751.04
8.74%
PATM
10.45%
12.15%
11.15%
12.14%
10.58%
12.82%
10.48%
10.40%
EPS
14.20
15.69
-9.50%
15.56
15.51
0.32%
14.56
15.98
-8.89%
14.07
12.92
8.90%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
32,024.85
31,723.73
29,001.87
24,855.38
23,455.49
24,774.62
23,098.51
19,563.55
16,463.03
14,909.54
13,794.65
Net Sales Growth
7.76%
9.39%
16.68%
5.97%
-5.32%
7.26%
18.07%
18.83%
10.42%
8.08%
 
Cost Of Goods Sold
13,192.78
11,671.89
11,348.78
10,190.48
9,238.91
8,827.71
8,720.74
7,886.32
6,085.55
5,911.00
5,612.30
Gross Profit
18,832.07
20,051.84
17,653.09
14,664.90
14,216.58
15,946.91
14,377.77
11,677.23
10,377.48
8,998.54
8,182.35
GP Margin
58.80%
63.21%
60.87%
59.00%
60.61%
64.37%
62.25%
59.69%
63.04%
60.35%
59.32%
Total Expenditure
25,485.78
25,140.94
23,158.87
21,136.74
19,070.95
19,441.22
18,234.20
15,611.61
12,691.28
11,475.26
10,606.53
Power & Fuel Cost
-
1,012.25
826.03
842.63
626.86
589.28
587.68
556.79
470.95
437.14
419.26
% Of Sales
-
3.19%
2.85%
3.39%
2.67%
2.38%
2.54%
2.85%
2.86%
2.93%
3.04%
Employee Cost
-
4,475.62
3,922.94
3,522.25
3,450.92
3,535.02
3,219.18
2,584.87
2,130.84
1,767.76
1,542.62
% Of Sales
-
14.11%
13.53%
14.17%
14.71%
14.27%
13.94%
13.21%
12.94%
11.86%
11.18%
Manufacturing Exp.
-
3,556.25
3,191.71
2,810.03
2,502.98
2,875.39
2,331.41
2,037.95
1,611.12
1,309.64
1,256.18
% Of Sales
-
11.21%
11.01%
11.31%
10.67%
11.61%
10.09%
10.42%
9.79%
8.78%
9.11%
General & Admin Exp.
-
1,551.60
1,483.77
1,386.66
1,335.03
1,473.59
1,320.69
1,006.68
1,068.22
997.32
686.38
% Of Sales
-
4.89%
5.12%
5.58%
5.69%
5.95%
5.72%
5.15%
6.49%
6.69%
4.98%
Selling & Distn. Exp.
-
2,185.06
1,684.72
1,685.76
1,496.67
1,564.17
1,524.75
1,125.76
1,025.85
848.43
877.14
% Of Sales
-
6.89%
5.81%
6.78%
6.38%
6.31%
6.60%
5.75%
6.23%
5.69%
6.36%
Miscellaneous Exp.
-
688.27
700.92
698.93
419.58
576.06
529.75
413.24
298.75
203.97
877.14
% Of Sales
-
2.17%
2.42%
2.81%
1.79%
2.33%
2.29%
2.11%
1.81%
1.37%
1.54%
EBITDA
6,539.07
6,582.79
5,843.00
3,718.64
4,384.54
5,333.40
4,864.31
3,951.94
3,771.75
3,434.28
3,188.12
EBITDA Margin
20.42%
20.75%
20.15%
14.96%
18.69%
21.53%
21.06%
20.20%
22.91%
23.03%
23.11%
Other Income
533.40
621.85
557.38
290.59
322.58
380.85
191.87
155.32
101.98
115.89
203.80
Interest
443.95
457.24
289.71
140.48
48.64
74.49
305.13
262.60
77.72
66.72
256.70
Depreciation
1,650.94
1,649.42
1,521.66
1,244.58
1,126.52
1,055.39
966.71
667.95
557.97
427.63
392.37
PBT
4,977.58
5,097.98
4,589.01
2,624.17
3,531.96
4,584.37
3,784.34
3,176.71
3,238.04
3,055.82
2,742.85
Tax
1,559.65
1,582.72
1,211.02
684.85
725.63
2,009.77
899.35
726.85
818.27
759.65
720.71
Tax Rate
31.33%
31.05%
27.54%
26.10%
21.32%
27.16%
23.93%
23.53%
25.27%
24.86%
26.28%
PAT
3,417.93
3,485.88
3,172.97
1,927.50
2,648.15
5,390.20
2,860.31
2,362.03
2,420.03
2,296.64
2,023.64
PAT before Minority Interest
3,419.79
3,483.57
3,168.97
1,927.65
2,647.11
5,389.18
2,858.86
2,361.80
2,419.77
2,296.17
2,022.14
Minority Interest
1.86
2.31
4.00
-0.15
1.04
1.02
1.45
0.23
0.26
0.47
1.50
PAT Margin
10.67%
10.99%
10.94%
7.75%
11.29%
21.76%
12.38%
12.07%
14.70%
15.40%
14.67%
PAT Growth
-3.26%
9.86%
64.62%
-27.21%
-50.87%
88.45%
21.10%
-2.40%
5.37%
13.49%
 
EPS
58.85
60.02
54.63
33.19
45.59
92.81
49.25
40.67
41.67
39.54
34.84

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
32,653.32
29,842.80
26,839.85
24,575.98
21,929.87
16,824.67
13,890.78
11,680.42
9,371.91
7,287.30
Share Capital
58.08
58.59
58.59
58.59
58.59
58.59
58.59
58.59
58.59
58.52
Total Reserves
32,595.24
29,784.21
26,781.26
24,517.39
21,871.28
16,766.08
13,832.13
11,621.76
9,313.22
7,227.50
Non-Current Liabilities
1,162.74
1,808.94
866.87
903.10
807.27
555.09
358.13
594.11
102.07
583.85
Secured Loans
1,159.38
2,134.90
618.96
249.21
168.49
0.00
48.88
451.20
177.59
380.10
Unsecured Loans
402.27
0.00
0.00
0.00
0.00
0.00
131.07
0.00
3.81
362.71
Long Term Provisions
282.93
225.70
172.72
171.79
157.11
74.71
46.54
55.86
39.13
23.36
Current Liabilities
14,682.34
12,199.13
11,493.78
8,155.98
10,665.05
11,384.64
12,020.57
8,665.89
6,605.60
7,840.22
Trade Payables
4,188.85
4,454.16
3,871.31
2,703.05
2,794.68
2,576.06
2,552.18
2,372.90
2,154.70
2,457.03
Other Current Liabilities
4,623.28
3,161.05
2,979.91
3,106.51
2,684.31
2,874.56
2,510.51
1,967.42
1,286.82
1,577.58
Short Term Borrowings
5,309.72
4,078.12
4,230.43
2,117.83
4,803.78
5,422.30
6,573.21
4,031.34
2,902.72
3,672.68
Short Term Provisions
560.49
505.80
412.13
228.59
382.28
511.72
384.67
294.23
261.36
132.93
Total Liabilities
48,492.01
43,858.87
39,212.50
33,633.13
33,401.31
28,764.54
26,271.07
20,942.24
16,081.66
15,713.92
Net Block
14,794.19
14,492.79
11,023.69
10,532.09
9,373.58
9,396.47
8,474.85
6,520.68
4,833.78
4,179.69
Gross Block
24,462.96
23,447.77
18,593.32
15,943.09
13,613.33
12,441.26
10,497.62
7,894.78
5,635.49
4,569.83
Accumulated Depreciation
9,659.15
8,952.24
7,569.63
5,411.00
4,239.75
3,044.79
2,022.77
1,374.10
801.71
390.14
Non Current Assets
21,329.55
19,653.24
17,666.83
15,510.44
13,577.80
12,352.03
10,938.77
8,764.08
6,875.48
5,419.57
Capital Work in Progress
4,899.96
3,868.72
5,390.01
3,747.20
3,061.53
1,985.92
1,668.46
1,583.04
1,458.08
848.14
Non Current Investment
251.70
321.65
391.74
618.30
431.22
554.69
360.20
311.52
245.85
122.94
Long Term Loans & Adv.
973.42
714.55
794.00
575.33
658.44
378.34
396.64
261.91
256.48
236.56
Other Non Current Assets
410.28
255.53
67.39
37.52
53.03
36.61
38.62
86.93
81.29
32.24
Current Assets
27,162.46
23,771.92
21,459.91
18,043.59
19,823.51
16,412.51
15,332.30
12,178.16
9,206.18
10,294.35
Current Investments
0.01
50.58
151.00
378.85
159.79
0.02
0.02
0.02
0.02
0.02
Inventories
10,543.72
9,808.23
8,511.23
7,553.85
9,026.57
7,699.87
7,245.60
5,858.41
4,330.54
4,056.14
Sundry Debtors
5,745.93
4,816.74
4,466.38
4,012.26
3,503.28
4,315.16
3,413.78
3,080.20
2,765.33
4,606.68
Cash & Bank
8,235.49
6,278.30
6,084.20
4,190.01
5,474.28
2,842.15
1,957.18
1,262.25
513.48
800.26
Other Current Assets
2,637.31
519.45
554.71
393.95
1,659.59
1,555.31
2,715.72
1,977.28
1,596.81
831.25
Short Term Loans & Adv.
1,983.31
2,298.62
1,692.39
1,514.67
1,058.30
1,065.96
795.90
753.96
512.09
366.88
Net Current Assets
12,480.12
11,572.79
9,966.13
9,887.61
9,158.46
5,027.87
3,311.73
3,512.27
2,600.58
2,454.13
Total Assets
48,492.01
43,425.16
39,126.74
33,554.03
33,401.31
28,764.54
26,271.07
20,942.24
16,081.66
15,713.92

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
3,924.62
2,434.52
2,386.75
5,016.48
3,329.05
4,381.28
1,650.97
1,954.52
3,278.58
1,419.76
PBT
5,066.29
4,379.99
2,612.50
3,372.74
7,343.59
3,743.04
3,091.35
3,241.18
3,060.84
2,744.30
Adjustment
1,834.16
1,496.24
1,586.47
1,344.13
-1,662.64
1,091.17
813.95
535.02
408.92
487.50
Changes in Working Capital
-1,244.48
-1,675.07
-1,094.98
1,557.80
-1,066.65
307.91
-1,484.50
-1,123.12
582.52
-1,079.41
Cash after chg. in Working capital
5,655.97
4,201.16
3,103.99
6,274.67
4,614.30
5,142.12
2,420.80
2,653.08
4,052.28
2,152.39
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,731.35
-1,766.64
-717.24
-1,258.19
-1,285.25
-760.84
-769.83
-698.56
-773.70
-732.63
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,875.80
-4,255.95
-3,977.75
-3,211.56
598.69
-1,567.64
-2,902.59
-1,926.59
-1,787.04
-1,445.21
Net Fixed Assets
-141.97
2,277.63
-503.75
1,473.74
-428.03
-760.60
-799.00
-771.00
-1,092.24
125.11
Net Investments
-1,816.13
-5,288.07
-1,521.01
-1,574.43
-2,482.52
-188.35
-371.56
-285.55
-498.60
-170.60
Others
82.30
-1,245.51
-1,952.99
-3,110.87
3,509.24
-618.69
-1,732.03
-870.04
-196.20
-1,399.72
Cash from Financing Activity
119.78
800.42
1,814.41
-2,969.27
-1,364.94
-1,947.18
1,919.06
864.15
-1,915.26
365.44
Net Cash Inflow / Outflow
2,168.60
-1,021.01
223.41
-1,164.35
2,562.80
866.46
667.44
892.08
-423.72
339.99
Opening Cash & Equivalents
3,385.43
4,392.27
4,162.51
5,329.91
2,746.82
1,875.58
1,209.94
318.03
743.49
403.81
Closing Cash & Equivalent
5,563.79
3,385.43
4,392.27
4,162.51
5,329.91
2,746.82
1,875.58
1,209.94
319.63
743.50

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
562.21
509.35
458.10
419.46
374.29
287.16
237.08
199.36
159.96
124.50
ROA
7.54%
7.63%
5.29%
7.90%
17.34%
10.39%
10.00%
13.07%
14.44%
14.13%
ROE
11.15%
11.18%
7.50%
11.38%
27.81%
18.62%
18.47%
22.99%
27.57%
32.51%
ROCE
14.39%
13.76%
9.39%
12.71%
30.33%
18.79%
17.97%
22.72%
24.92%
27.35%
Fixed Asset Turnover
2.65
2.84
2.95
3.24
3.73
4.12
4.36
2.44
2.96
2.79
Receivable days
30.33
28.34
30.42
28.69
29.37
29.85
29.56
64.66
89.16
106.53
Inventory Days
58.44
55.92
57.65
63.29
62.82
57.72
59.64
112.70
101.43
100.27
Payable days
135.14
133.88
117.74
108.60
111.03
53.30
58.56
67.77
75.73
81.70
Cash Conversion Cycle
-46.37
-49.62
-29.67
-16.62
-18.84
34.27
30.63
109.58
114.86
125.10
Total Debt/Equity
0.24
0.21
0.18
0.10
0.23
0.33
0.50
0.41
0.36
0.69
Interest Cover
12.08
16.12
19.60
70.34
100.33
13.32
12.76
42.66
46.80
11.69

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • Aurobindo Pharma’s arm incorporates wholly owned subsidiary in Malta
    27th Sep 2025, 12:36 PM

    The object of incorporation of this wholly owned step-down subsidiary is to expand the Pharmaceutical Products business in Malta

    Read More
  • USFDA completes inspection at Aurobindo Pharma’s Unit-XII in Telangana
    6th Sep 2025, 12:31 PM

    The USFDA has issued ‘Form 483’ with total of 8 observations for both (oral solids & injectable)

    Read More
  • USFDA completes inspection at Aurobindo Pharma’s arm's API manufacturing facility in Telangana
    30th Aug 2025, 10:14 AM

    At the end of the current inspection, a ‘Form 483’ was issued with 5 observations which are procedural in nature and no data integrity issues were reported

    Read More
  • Aurobindo Pharma’s arm obtains marketing authorization for Dazublys in UK
    26th Aug 2025, 10:30 AM

    Earlier in July 2025, Dazublys has received the marketing authorisation in the European Union from the European Commission

    Read More
  • Aurobindo Pharma - Quarterly Results
    4th Aug 2025, 19:26 PM

    Read More
  • Aurobindo Pharma’s arm to acquire 100% membership interest in Lannett Company LLC
    31st Jul 2025, 10:12 AM

    The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities

    Read More
  • Aurobindo Pharma to manufacture, supply long-acting HIV treatment cabotegravir across 133 countries
    15th Jul 2025, 15:42 PM

    This is a significant and timely step towards increasing access to advanced long-acting treatment in LMICs

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.